Market closedNon-fractional
Cytokinetics/CYTK
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Cytokinetics
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Ticker
CYTK
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
South San Francisco, United States
Employees
423
Website
www.cytokinetics.com
Cytokinetics Metrics
BasicAdvanced
$6.8B
Market cap
-
P/E ratio
-$5.40
EPS
0.75
Beta
-
Dividend rate
Price and volume
Market cap
$6.8B
Beta
0.75
Financial strength
Current ratio
7.188
Quick ratio
6.966
Long term debt to equity
-183.049
Total debt to equity
-190.559
Interest coverage (TTM)
-8.06%
Management effectiveness
Return on assets (TTM)
-36.66%
Return on equity (TTM)
169.74%
Valuation
Price to revenue (TTM)
1,531.333
Price to book
-15.5
Price to tangible book (TTM)
-15.5
Price to free cash flow (TTM)
-13.597
Growth
Revenue change (TTM)
-96.17%
Earnings per share change (TTM)
15.83%
3-year revenue growth (CAGR)
-59.98%
3-year earnings per share growth (CAGR)
39.28%
What the Analysts think about Cytokinetics
Analyst Ratings
Majority rating from 18 analysts.
Cytokinetics Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$800K
-50.00%
Net income
-$136M
-0.88%
Profit margin
-16,950.00%
98.25%
Cytokinetics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.34
-$1.35
-$1.38
-$1.33
-
Expected
-$1.15
-$0.74
-$0.97
-$1.14
-$1.08
Surprise
16.93%
81.86%
42.18%
16.47%
-
Cytokinetics News
AllArticlesVideos
Cytokinetics to Announce Second Quarter Results on August 8, 2024
GlobeNewsWire·1 day ago
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
GlobeNewsWire·3 weeks ago
Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cytokinetics stock?
Cytokinetics (CYTK) has a market cap of $6.8B as of July 27, 2024.
What is the P/E ratio for Cytokinetics stock?
The price to earnings (P/E) ratio for Cytokinetics (CYTK) stock is 0 as of July 27, 2024.
Does Cytokinetics stock pay dividends?
No, Cytokinetics (CYTK) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Cytokinetics dividend payment date?
Cytokinetics (CYTK) stock does not pay dividends to its shareholders.
What is the beta indicator for Cytokinetics?
Cytokinetics (CYTK) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Cytokinetics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.